<DOC>
	<DOCNO>NCT01110473</DOCNO>
	<brief_summary>The purpose study determine safety , pharmacokinetics maximum tolerate dose ABT-348 monotherapy give combination azacitidine .</brief_summary>
	<brief_title>ABT-348 Monotherapy Combination With Azacitidine Treat Advanced Hematologic Malignancies</brief_title>
	<detailed_description>The primary objective study determine safety pharmacokinetics ABT-348 monotherapy give combination azacitidine . The secondary objective determine maximum tolerate dose recommend Phase 2 dose ABT-348 administer monotherapy give combination azacitidine subject advance hematologic malignancy .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Histological cytological confirmation one following ( Arms A , B D ) : Relapsed refractory acute myelogenous leukemia ( AML ) , untreated AML subject &gt; 60 year age favorable cytogenetics ( i.e. , lack ( 8,21 ) inv ( 16 ) /t ( 16,16 ) acute lymphoblastic leukemia ( ALL ) subject fail unsuitable standard therapy . Chronic myelogenous leukemia ( CML ) subject respond relapse imatinib fail second line Tyrosine Kinase Inhibitor ( TKI ) therapy candidate allogeneic bone marrow transplant . Bcell chronic lymphocytic leukemia ( CLL ) subject respond relapsed fludarabine opinion Principal Investigator unsuitable fludarabine therapy respond relapsed alkylating therapy . Myelodysplasia ( MDS ) include chronic myelomonocytic leukemia ( CMML ) subject International Prognostic Scoring System ( IPSS ) risk category Intermediate2 ( INT2 ) High risk , myelodysplasia symptomatic anemia resistant erythropoietin , immunosuppressant , DNA methyltransferase inhibitor therapy ( e.g. , azacitidine/decitabine ) . 1a . Histological cytological confirmation one following ( Arm C ) : Relapsed refractory AML , untreated AML subject &gt; 60 year age favorable cytogenetics ( i.e. , lack ( 8,21 ) . Untreated MDS include CMML IPSS risk category INT2 High risk 10 % blast bone marrow , myelodysplasia symptomatic anemia resistant erythropoietin , immunosuppressant , subject response four cycle DNA methyltransferase inhibitor therapy subject progress DNA methyltransferase inhibitor therapy . 2 . Eastern Cooperative Oncology Group Status 02 3 . Hematologic function subject CLL CML demonstrate hemoglobin &gt; 9 g/dL , platelet &gt; 100,000/µL , ANC &gt; 1500/mm3 4 . Serum creatinine value ≤ 1.8 time upper limit normal ( ULN ) either estimate creatinine clearance value determine CockcroftGault formula base 24 hour urine collection creatinine clearance value ≥ 50 mL/min 5 . Adequate liver function demonstrate serum bilirubin &lt; 2 x ULN AST ALT &lt; 2.5 x ULN 6 . QTc interval &lt; 500 msec 7 . Left Ventricular Ejection Fraction &gt; 50 % 8 . Women childbearing potential men must agree use adequate contraception prior study entry , duration study participation 3 month follow completion therapy . 9 . Capable understand comply parameter outline protocol able sign inform consent , approve Institutional Review Board ( IRB ) prior initiation screen studyspecific procedure . 1 . Subject know active CNS involvement . The subject untreated brain meningeal metastasis . 2 . ALL AML subject receive acute anticancer therapy within 14 day prior Study Day 1 3 . CML , CLL myelodysplasia ( MDS ) subject receive acute anticancer therapy within 28 day biologic therapy within 6 week prior Study Day 1 . Per Investigator discretion , hydroxyurea may use anytime study . Tyrosine kinase inhibitor may administer 7 day prior Study Day 1 . 4 . Subjects poorly control diabetes mellitus 5 . Subject unresolved toxicity prior anticancer therapy , grade 2 high clinically significant toxicity ( exclude alopecia ) 6 . Subject major surgery within 28 day prior Study Day 1 7 . Subject currently exhibit symptomatic persistent , uncontrolled hypertension define diastolic blood pressure &gt; 90 mmHg systolic blood pressure &gt; 140 mmHg 8 . Subject proteinuria grade &gt; 1 9 . Subject unable swallow absorb oral tablet normally 10 . Subject receive therapeutic anticoagulation therapy . Lowdose anticoagulation ( e.g. , lowdose heparin warfarin ) catheter prophylaxis allow 11 . Subject infection HIV , Hepatitis B , Hepatitis C 12 . Female subject pregnant breast feed 13 . Any medical condition opinion study investigator place subject unacceptably high risk toxicity 14 . Clinically significant uncontrolled condition ( ) 15 . Subjects Arm C advance malignant hepatic tumor 16 . Subjects Arm C hypersensitivity azacitidine mannitol 17 . Subjects receive CYP3A inhibitor inducer within 7 day prior first dose study drug . 18 . Subjects enrol Arm D hypersensitivity drug formulate polyethoxylated castor oil ( Cremophor ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>